12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients [clinicaltrials:NCT00789035]

Bio2RDF uri

12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients [clinicaltrials:NCT00789035]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00789035

Bio2RDF identifier

NCT00789035

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00789035

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00789035

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

408

http://www.w3.org/2001/XMLSchema#integer

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:723a43b0181ae22d37dc198cf8fc5de8

baseline [clinicaltrials_vocabulary:baseline]

baseline for NCT00789035 [clinicaltrials_resource:NCT00789035/baseline]

brief summary [clinicaltrials_vocabulary:brief-summary]

The objective is to inv ...... in arm will be assessed

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients

http://www.w3.org/2001/XMLSchema#string

clinical result [clinicaltrials_vocabulary:clinical-result]

clinical results for clinicaltrials:NCT00789035 [clinicaltrials_resource:bb213fe364252165ee0ccf9ae0452b3a]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment Baseline and 12 weeks [clinicaltrials_resource:a4dc694524ad0fb453873e2461d8c77f]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment Baseline and 12 weeks [clinicaltrials_resource:087cbe7548a7f307fa13f3f1b8debce0]

Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment Baseline and 12 weeks [clinicaltrials_resource:17748d5204720cf527426da53bd673fe]

Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment Baseline and 12 weeks [clinicaltrials_resource:2928ae2c3d61f630c6a7aceaded52360]

Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment Baseline and 12 weeks [clinicaltrials_resource:38679dc79d8296926ede6591157a879a]

Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment Baseline and 12 weeks [clinicaltrials_resource:a357d895092b0afeca5d241df1f5a388]

Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment Baseline and 12 weeks [clinicaltrials_resource:b6699f5e199c36ba163556972fb52e59]

Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment Baseline and 12 weeks [clinicaltrials_resource:f52e57bffcbef7e91fb3a4764065d89a]

Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment Baseline and 12 weeks [clinicaltrials_resource:f8b3d33efbb3f1105f5435a6fb718fd3]

Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment Baseline and 12 weeks [clinicaltrials_resource:ff66b8367e272570478c83ac521119bf]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00789035 [clinicaltrials_resource:007edbd33fda95bffb036b7f6fae6af6]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2008-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

firstreceived results date [clinicaltrials_vocabulary:firstreceived-results-date]

2014-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

placebo [clinicaltrials_resource:771772a364439361998298c491c1a544]

metformin [clinicaltrials_resource:798452363d03ec019c7abdcf7a21bff1]

BI 10773 [clinicaltrials_resource:f1fba1c943123fea74fe3b76bc61c851]

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2014-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Boehringer Ingelheim [clinicaltrials_resource:5d012cfae6e8b67d8437e7145ea9a68f]

link [clinicaltrials_vocabulary:link]

[clinicaltrials_resource:3cc6bb634ff402eafe042fcf4cd8bb03]

[clinicaltrials_resource:a278f5b7434a677d6cd006e077a6947f]

location [clinicaltrials_vocabulary:location]

1245.9.54001 Boehringer Ingelheim Investigational Site [clinicaltrials_resource:13c477a9b590eeacacd041a39c56dbdf]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00789035

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

A Phase IIb, Randomized, Paral ...... Insufficient Glycemic Control

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

1.2459000244140626e+3

http://www.w3.org/2001/XMLSchema#float

outcome [clinicaltrials_vocabulary:outcome]

Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment [clinicaltrials_resource:NCT00789035/outcome/1]

overall official [clinicaltrials_vocabulary:overall-official]

Boehringer Ingelheim [clinicaltrials_resource:1f5af28df428803ccefd08f103ea82a2]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Argentina: A.N.M.A.T. (National Administration of Medications, Food and Medical Technology) [clinicaltrials_resource:c1f1cc4b85db1abed072b338d16766db]

participant flow [clinicaltrials_vocabulary:participant-flow]

participant flow for clinicaltrials:NCT00789035 [clinicaltrials_resource:2cd9b783b8f9863d460045b3c9a9be22]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reported events [clinicaltrials_vocabulary:reported-events]

Reported events for NCT00789035 [clinicaltrials_resource:c33e69eb4ee2ce228d61c2b7366e4652]

responsible party [clinicaltrials_vocabulary:responsible-party]

Boehringer Ingelheim, Study Chair, Boehringer Ingelheim [clinicaltrials_resource:647bb26ee689091d3c2c5b3dc0e985bd]

secondary id [clinicaltrials_vocabulary:secondary-id]

EudraCT No 2008-000640-14

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Boehringer Ingelheim [clinicaltrials_resource:5d012cfae6e8b67d8437e7145ea9a68f]

start date [clinicaltrials_vocabulary:start-date]

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00789035 study design [clinicaltrials_resource:b8987c0527add2567218a12b50089882]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00789035

verification date [clinicaltrials_vocabulary:verification-date]

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00789035

http://www.w3.org/2001/XMLSchema#string

title

12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

12 Weeks Treatment With 3 Diff ...... s [clinicaltrials:NCT00789035]

@en